Evolution of Low- and Intermediate-Mass Stars with [Fe/H] <= -2.5

We present extensive sets of stellar models for 0.8-9.0Msun in mass and -5 <= [Fe/H] <= -2 and Z = 0 in metallicity. The present work focuses on the evolutionary characteristics of hydrogen mixing into the He-flash convective zones during the core and shell He flashes which occurs for the models with [Fe/H] <~ -2.5. Evolution is followed from the zero age MS to the TPAGB phase including the hydrogen engulfment by the He-flash convection during the RGB or AGB phase. There exist various types of mixing episodes of how the H mixing sets in and how it affects the final abundances at the surface. In particular, we find H ingestion events without dredge-ups that enables repeated neutron-capture nucleosynthesis in the He flash convective zones with 13 C(a,n)16 O as neutron source. For Z = 0, the mixing and dredge-up processes vary with the initial mass, which results in different final abundances in the surface. We investigate the occurrence of these events for various initial mass and metallicity to find the metallicity dependence for the He-flash driven deep mixing (He-FDDM) and also for the third dredge-up (TDU) events. In our models, we find He-FDDM for M <= 3Msun for Z = 0 and for M <~ 2Msun for -5 <~ [Fe/H] <~ -3. On the other hand, the occurrence of the TDU is limited to the mass range of ~1.5Msun to ~5Msun for [Fe/H] = -3, which narrows with decreasing metallicity. The paper also discusses the implications of the results of model computations for observations. We compared the abundance pattern of CNO abundances with observed metal-poor stars. The origins of most iron-deficient stars are discussed by assuming that these stars are affected by binary mass transfer. We also point out the existence of a blue horizontal branch for -4 <~ [Fe/H] <~ -2.5.Comment: 19 pages, 12 figures, accepted by MNRA

Reaction rates and transport in neutron stars

Understanding signals from neutron stars requires knowledge about the transport inside the star. We review the transport properties and the underlying reaction rates of dense hadronic and quark matter in the crust and the core of neutron stars and point out open problems and future directions.Comment: 74 pages; commissioned for the book "Physics and Astrophysics of Neutron Stars", NewCompStar COST Action MP1304; version 3: minor changes, references updated, overview graphic added in the introduction, improvements in Sec IV.A.

The Circumgalactic Medium in Massive Halos

This chapter presents a review of the current state of knowledge on the cool (T ~ 1e4 K) halo gas content around massive galaxies at z ~ 0.2-2. Over the last decade, significant progress has been made in characterizing the cool circumgalactic gas in massive halos of Mh ~ 1e12-1e14 Msun at intermediate redshifts using absorption spectroscopy. Systematic studies of halo gas around massive galaxies beyond the nearby universe are made possible by large spectroscopic samples of galaxies and quasars in public archives. In addition to accurate and precise constraints for the incidence of cool gas in massive halos, detailed characterizations of gas kinematics and chemical compositions around massive quiescent galaxies at z ~ 0.5 have also been obtained. Combining all available measurements shows that infalling clouds from external sources are likely the primary source of cool gas detected at d >~ 100 kpc from massive quiescent galaxies. The origin of the gas closer in is currently less certain, but SNe Ia driven winds appear to contribute significantly to cool gas found at d < 100 kpc. In contrast, cool gas observed at d <~ 200 kpc from luminous quasars appears to be intimately connected to quasar activities on parsec scales. The observed strong correlation between cool gas covering fraction in quasar host halos and quasar bolometric luminosity remains a puzzle. Combining absorption-line studies with spatially-resolved emission measurements of both gas and galaxies is the necessary next step to address remaining questions.Comment: 29 pages, 7 figures, invited review to appear in "Gas Accretion onto Galaxies", Astrophysics and Space Science Library, eds. A. Fox & R. Dave, to be published by Springe

Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271.

The question of whether tumorigenic cancer stem cells exist in human melanomas has arisen in the last few years. Here we show that in melanomas, tumour stem cells (MTSCs, for melanoma tumour stem cells) can be isolated prospectively as a highly enriched CD271(+) MTSC population using a process that maximizes viable cell transplantation. The tumours sampled in this study were taken from a broad spectrum of sites and stages. High-viability cells isolated by fluorescence-activated cell sorting and re-suspended in a matrigel vehicle were implanted into T-, B- and natural-killer-deficient Rag2(-/-)gammac(-/-) mice. The CD271(+) subset of cells was the tumour-initiating population in 90% (nine out of ten) of melanomas tested. Transplantation of isolated CD271(+) melanoma cells into engrafted human skin or bone in Rag2(-/-)gammac(-/-) mice resulted in melanoma; however, melanoma did not develop after transplantation of isolated CD271(-) cells. We also show that in mice, tumours derived from transplanted human CD271(+) melanoma cells were capable of metastatsis in vivo. CD271(+) melanoma cells lacked expression of TYR, MART1 and MAGE in 86%, 69% and 68% of melanoma patients, respectively, which helps to explain why T-cell therapies directed at these antigens usually result in only temporary tumour shrinkage

Convective Core Mixing: a Metallicity Dependence?

The main scope of this paper is to investigate the possible existence of a metallicity dependence of the overshooting from main sequence stars turbulent cores. We focus on objects with masses in the range ~2.5 Msol - ~25 Msol. Basically, evolutionary time scale ratios are compared with star numbers ratios on the main sequence. Star populations are synthesized using grids of evolutionary tracks computed with various overshooting amounts. Observational material is provided by the large and homogeneous photometric database of OGLE 2 project for the Magellanic clouds. Attention is paid to the study of uncertainties: distance modulus, intergalactic and interstellar reddening, IMF slope and average binarity rate. Rotation and chemical composition gradient are also considered. The result for the overshooting distance is l_over(SMC)= 0.40 +0.12-0.06 Hp (Z=0.004) and l_over(LMC)= 0.10+0.17-0.10 Hp (Z=0.008) suggesting a possible dependence of the extent of the mixed central regions with metallicity within the considered mass range. Unfortunately it is not yet possible to fully disentangle effects of mass and chemical composition.Comment: 13 pages, 8 figures, accepted in Astronomy & Astrophysic

Systematic review for non-surgical interventions for the management of late radiation proctitis

Chronic radiation proctitis produces a range of clinical symptoms for which there is currently no recommended standard management. The aim of this review was to identify the various non-surgical treatment options for the management of late chronic radiation proctitis and evaluate the evidence for their efficacy. Synonyms for radiation therapy and for the spectrum of lower gastrointestinal radiation toxicity were combined in an extensive search strategy and applied to a range of databases. The included studies were those that involved interventions for the non-surgical management of late radiation proctitis. Sixty-three studies were identified that met the inclusion criteria, including six randomised controlled trials that described the effects of anti-inflammatory agents in combination, rectal steroids alone, rectal sucralfate, short chain fatty acid enemas and different types of thermal therapy. However, these studies could not be compared. If the management of late radiation proctitis is to become evidence based, then, in view of its episodic and variable nature, placebo controlled studies need to be conducted to clarify which therapeutic options should be recommended. From the current data, although certain interventions look promising and may be effective, one small or modest sized study, even if well-conducted, is insufficient to implement changes in practice. In order to increase recruitment to trials, a national register of cases with established late radiation toxicity would facilitate multi-centre trials with specific entry criteria, formal baseline and therapeutic assessments providing standardised outcome data

The Physics of the B Factories

This work is on the Physics of the B Factories. Part A of this book contains a brief description of the SLAC and KEK B Factories as well as their detectors, BaBar and Belle, and data taking related issues. Part B discusses tools and methods used by the experiments in order to obtain results. The results themselves can be found in Part C

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

Background: The EMPA KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through slowing progression. We aimed to assess how effects of empagliflozin might differ by primary kidney disease across its broad population. Methods: EMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA). Patients were eligible if their estimated glomerular filtration rate (eGFR) was 20 to less than 45 mL/min per 1·73 m2, or 45 to less than 90 mL/min per 1·73 m2 with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or higher at screening. They were randomly assigned (1:1) to 10 mg oral empagliflozin once daily or matching placebo. Effects on kidney disease progression (defined as a sustained ≥40% eGFR decline from randomisation, end-stage kidney disease, a sustained eGFR below 10 mL/min per 1·73 m2, or death from kidney failure) were assessed using prespecified Cox models, and eGFR slope analyses used shared parameter models. Subgroup comparisons were performed by including relevant interaction terms in models. EMPA-KIDNEY is registered with ClinicalTrials.gov, NCT03594110. Findings: Between May 15, 2019, and April 16, 2021, 6609 participants were randomly assigned and followed up for a median of 2·0 years (IQR 1·5–2·4). Prespecified subgroupings by primary kidney disease included 2057 (31·1%) participants with diabetic kidney disease, 1669 (25·3%) with glomerular disease, 1445 (21·9%) with hypertensive or renovascular disease, and 1438 (21·8%) with other or unknown causes. Kidney disease progression occurred in 384 (11·6%) of 3304 patients in the empagliflozin group and 504 (15·2%) of 3305 patients in the placebo group (hazard ratio 0·71 [95% CI 0·62–0·81]), with no evidence that the relative effect size varied significantly by primary kidney disease (pheterogeneity=0·62). The between-group difference in chronic eGFR slopes (ie, from 2 months to final follow-up) was 1·37 mL/min per 1·73 m2 per year (95% CI 1·16–1·59), representing a 50% (42–58) reduction in the rate of chronic eGFR decline. This relative effect of empagliflozin on chronic eGFR slope was similar in analyses by different primary kidney diseases, including in explorations by type of glomerular disease and diabetes (p values for heterogeneity all &gt;0·1). Interpretation: In a broad range of patients with chronic kidney disease at risk of progression, including a wide range of non-diabetic causes of chronic kidney disease, empagliflozin reduced risk of kidney disease progression. Relative effect sizes were broadly similar irrespective of the cause of primary kidney disease, suggesting that SGLT2 inhibitors should be part of a standard of care to minimise risk of kidney failure in chronic kidney disease. Funding: Boehringer Ingelheim, Eli Lilly, and UK Medical Research Council